Clinical trial · Interventional
Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' Dawn Test
Establishing Clinical Utility Evidence to Support Coverage and Reimbursement for Venn Biosciences' DawnTM: A CPV® Randomized Controlled Trial
NCT05603299CI-TRIAL-00067156withdrawnN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): The study recruited no participants due to a pre-recruitment decision by the sponsor to not proceed. Factors considered included logistics, resources, and new research data.
Summary
Brief summary (as posted)
QURE will use its CPV technology in a randomized controlled trial to measure how InterVenn Biosciences diagnostic test changes clinical practice and improves patient outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Educational Materials on the Dawn test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- NO_INTERVENTION
- label
- Control Group
- description
- The Control group treats their simulated patients using standard practice and have no introduction to the new test.
- type
- EXPERIMENTAL
- label
- Intervention Group 1 - Test Results Given
- description
- Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, whether they order the test or not.
- interventionNames
- Other: Educational Materials on the Dawn test
- type
- EXPERIMENTAL
- label
- Intervention Group 2 - Test Results Optional
- description
- Receiving educational materials describing the clinical validation and use cases of a predefined Dawn™ test and is given specific Dawn™ test results in Round 2 of CPV administration, only if they choose to order the test.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Board-certified medical oncologists for at least two years * Averaging at least 20 hours per week of clinical and patient care duties over the last six months * Routinely evaluate patients with advanced/metastatic NSCLC in their practice * Prescribe IO therapies for their advanced/metastatic NSCLC patients * Practice in either an academic, non-academic, or network hospital setting * Practicing in the U.S. * English speaking * Access to the internet * Informed, signed, and voluntarily consented to be in the study Exclusion Criteria: * Not board-certified in oncology * Not English speaking * Not averaging at least 20 hours per week of clinical and patient care duties over the last six months * Not practicing in the U.S. * No access to the internet * Did not voluntarily consent to be in the study
References
Publications (0)
Data not yet available
No reference posted for this study.